HR Execs on the Move


 
Seagen Inc. is an American biotechnology company focused on developing and commercializing innovative, empowered monoclonal antibody-based therapies for the treatment of cancer.
  • Number of Employees: 1K-5K
  • Annual Revenue: $500M-1 Billion
  • www.seagen.com
  • 21823, 30th Drive Southeast
    Bothell, WA USA 98021
  • Phone: 425.527.4000

Executives

Name Title Contact Details
Frank Jordan
Director HR Data Reporting and Analytics Profile
Colleen Peterson
Executive Director Human Resources Profile
Stephanie Lam
Associate Director Human Resources, HRBP Profile
Bart Cornelissen
Vice President Corporate Finance Profile
Karen Manalang
Associate Director, Accounting Profile

Similar Companies

Koronis Pharmaceuticals

Koronis Pharmaceuticals is a Redmond, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Cell Therapeutics

Cell Therapeutics, Inc is a Seattle, WA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Thallion Pharmaceuticals

Thallion Pharmaceuticals is a Saint-Laurent, QC-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Lynxcom Partners

Lynxcom Partners LLC is a Del Mar, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Codiak Biosciences

Codiak is the leader in the emerging field of exosome therapeutics, working to harness the power of this cellular messenger system to create potentially life-changing medicines. A venture-backed startup founded in 2015, Codiak has rapidly built a proprietary technology platform for exosome engineering and manufacturing that allows for precise targeting of important molecular pathways, opening the door to the development of therapies for cancer and other diseases. Led by an experienced and dedicated team, Codiak has at its foundation a positive and collaborative culture that is deeply rooted in cutting edge science and promotes opportunity for growth. Recent discoveries have transformed our understanding of the role of exosomes in the body. We now know that these natural, cell-derived vesicles can act as a potent and safe delivery system for multiple therapeutic payloads. Recognizing the enormous potential of exosomes, Codiak is applying leading-edge translational science and rigorous drug development to build a pipeline of candidates with broad utility and the capacity to address currently “undruggable” targets. While our initial focus is on oncology/immuno-oncology, this approach also offers significant potential in hematology, neurology and gene therapy and other therapy areas. At Codiak, we are working to create a major shift in the development of tomorrow`s medicines through scientific ambition, remarkable ingenuity and deep passion for improving patients` lives. Located in the heart of Boston`s biotechnology hub in Cambridge, Massachusetts, we are advancing a bold vision by tapping into the unique talents of a varied pool of individuals who together are achieving truly exceptional work.